Table 2.
Relative change in retention factor for sulfonylurea drugs on a normal and glycated HSA columns in the presence of various fatty acids
| Fatty acid (Concentration range) |
Drug and relative change in retention | |||
|---|---|---|---|---|
| Acetohexamide | Gliclazide | Tolbutamide | Glybenclamideb | |
| Normal HSA | ||||
| Lauric acid (0-60 nM) | 27% | 41% | 26% | 8% |
| Linoleic acid (0-250 nM) | 3% | 4% | 4% | 15% |
| Myristic acid (0-30 nM) | 27% | 33% | 22% | (7%)b |
| Oleic acid (0-546 nM) | 15% | 8% | 16% | 11% |
| Palmitic acid (0-400 nM) | 10% | 15% | 11% | 11% |
| Stearic acid (0-80 nM) | 5% | 4% | 4% | 2% |
| Glycated HSA | ||||
| Lauric acid (0-6 nM) | 14% | 18% | 13% | 15% |
| Linoleic acid (0-250 nM) | 18% | 22% | 18% | 17% |
| Myristic acid (0-30 nM) | 25% | 31% | 23% | 15% |
| Oleic acid (0-546 nM) | 9% | 15% | 11% | 12% |
| Palmitic acid (0-400 nM) | 81% | 79% | 84% | 52% |
| Stearic acid (0-80 nM) | 20% | 26% | 20% | 18% |
a
All of these studies were conducted at 37°C in the presence of pH 7.4, 67 mM potassium phosphate buffer.
b
All of the above relative changes represent a decrease in retention except for glybenclamide in the presence of myristic acid, which gave a slight increase in retention at the highest tested concentration of this fatty acid.